You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 10, 2025

Drugs in MeSH Category Voltage-Gated Sodium Channel Blockers


✉ Email this page to a colleague

« Back to Dashboard


Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Vangard PROCAINAMIDE HYDROCHLORIDE procainamide hydrochloride CAPSULE;ORAL 087643-001 Jun 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Watson Labs PROCAINAMIDE HYDROCHLORIDE procainamide hydrochloride CAPSULE;ORAL 084280-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Aurobindo Pharma Ltd PROPAFENONE HYDROCHLORIDE propafenone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 213096-003 Feb 21, 2023 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
Zydus Lifesciences PROPAFENONE HYDROCHLORIDE propafenone hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 214184-002 Apr 21, 2021 AB RX No No ⤷  Try for Free ⤷  Try for Free ⤷  Try for Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Voltage-Gated Sodium Channel Blockers Market Analysis and Financial Projection

Last updated: March 25, 2025

The global market for voltage-gated sodium channel blockers is undergoing significant transformation, driven by evolving therapeutic applications and patent-driven innovation. Here's a comprehensive analysis:


Market Dynamics

The global sodium channel blockers market was valued at \$5.64 billion in 2023, projected to reach \$9.96 billion by 2030 at an 8.5% CAGR[2][10][12]. Key factors include:

  • Clinical demand: Rising prevalence of cardiac arrhythmias, epilepsy, and chronic pain disorders (particularly neuropathic pain)[2][8].
  • Demographic shifts: Aging populations increasing neurological and cardiovascular disease burdens[2][10].
  • Regional trends:
    • North America dominates due to robust R&D infrastructure[2][12]
    • Asia-Pacific emerges as the fastest-growing market, fueled by healthcare investments[10]

Challenges:

  • First-generation drugs (e.g., lidocaine derivatives) face limitations due to non-selectivity and side effects[5][8]
  • Patent expiries (e.g., lacosamide’s 2028 cliff[2]) accelerating generic competition

Patent Landscape

Recent innovations focus on subtype-selective targeting, particularly Nav1.7/Nav1.8 for pain management:

Key Patent Trends

Company Patent Focus Target Indication
Pfizer Sulfonamide Nav1.7 inhibitors[4] Chronic pain
Merck Pyrrolo-benzo-diazine compounds[4] Neurological disorders
Vertex TTX-S channel modulators[5] Epilepsy/pain

Structural breakthroughs (2021–2025):

  • Cryo-EM mapping of Nav1.7-GX-936 complex enabled precision drug design[7]
  • Computational peptide engineering improving Nav1.7 selectivity (PTx2-3066 shows <1% cross-activity with Nav1.5)[16]

Therapeutic Innovation Pipeline

Second-generation candidates:

  • GDC-0276/0310: Nav1.7 inhibitors with sub-nanomolar potency[7]
  • State-dependent modulators: Ralfinamide combines NaV/NMDA receptor action[5]
  • Toxin-inspired therapies: Scorpion α-toxin analogs targeting VSD4 inactivation[6][15]

Strategic Considerations

  • IP protection strategies: 63% of recent patents focus on Nav1.7-specific chemotypes[4][13]
  • Market differentiation:
    • Biogen/SK biopharmaceuticals investing in brain-impenetrable peripherally-acting blockers[10][12]
    • Daewoong targeting TRPV1-NaV combinatorial approaches for neuropathic pain[12]

"The resurgence of sodium channel research lies in combining structural biology with computational design to overcome selectivity barriers" – Frontiers in Pharmacology[15].

This dynamic landscape positions sodium channel blockers as a \$10 billion frontier, where patent-driven molecular precision will increasingly dictate therapeutic success and market leadership.

References

  1. https://patents.google.com/patent/US8779197B2/en
  2. https://www.coherentmi.com/industry-reports/global-sodium-channel-blockers-market
  3. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.737637/full
  4. https://db.idrblab.net/ttd/data/patent/details/t12119
  5. https://pmc.ncbi.nlm.nih.gov/articles/PMC4850042/
  6. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.858348/full
  7. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.842032/full
  8. https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2011.00054/full
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC3885250/
  10. https://www.360iresearch.com/library/intelligence/sodium-channel-blockers
  11. https://rupress.org/jgp/article/157/2/e202413669/277220/The-differential-impacts-of-equivalent-gating
  12. https://www.openpr.com/news/3648138/explosive-growth-predicted-for-global-sodium-channel-blockers
  13. https://pubmed.ncbi.nlm.nih.gov/25539043/
  14. http://www.sioc.ac.cn/lib/inforres/resources/202406/P020240624366379933576.pdf
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC8968173/
  16. https://www.biorxiv.org/content/10.1101/2022.07.21.500925v1.full.pdf

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.